Literature DB >> 10102408

Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

N Turjanski1, A J Lees, D J Brooks.   

Abstract

OBJECTIVE: To use PET to study striatal dopaminergic function in restless legs syndrome (RLS).
BACKGROUND: RLS is a common disorder experienced by as much as 5% of the population. It has been suggested that this condition is associated with a disturbance of dopaminergic transmission.
METHODS: The authors measured nigrostriatal terminal dopamine storage with 18F-dopa and striatal D2 receptor binding with 11C-raclopride PET in 13 RLS patients, five of whom were receiving treatment with L-dopa at the time of scanning. RLS results were compared with those of age-matched control subjects.
RESULTS: Mean caudate and putamen 18F-dopa uptake were mildly reduced in the RLS patients compared with control subjects, and this reached significance (p = 0.04) in the putamen. Mean D2 binding was reduced in the caudate (p = 0.01) and the putamen (p = 0.008) in RLS patients compared with control subjects. Six of the 13 RLS patients had caudate and putamen D2 binding reduced below the control range. Three other RLS patients showed only reduced putamen D2 binding. There were no significant differences in striatal 18F-dopa uptake or D2 binding between L-dopa-naive and L-dopa-treated RLS patients.
CONCLUSIONS: These PET findings support the hypothesis of central dopaminergic dysfunction in RLS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102408     DOI: 10.1212/wnl.52.5.932

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  81 in total

1.  Restless Legs Syndrome.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-09       Impact factor: 3.598

Review 2.  Role of dopamine receptor agonists in the treatment of restless legs syndrome.

Authors:  Svenja Happe; Claudia Trenkwalder
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  Ropinirole versus levodopa in Parkinson's disease.

Authors:  John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

Review 4.  Restless legs syndrome: pathophysiology, clinical presentation and management.

Authors:  Claudia Trenkwalder; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2010-06       Impact factor: 42.937

5.  History of the development of sleep medicine in the United States.

Authors:  John W Shepard; Daniel J Buysse; Andrew L Chesson; William C Dement; Rochelle Goldberg; Christian Guilleminault; Cameron D Harris; Conrad Iber; Emmanuel Mignot; Merrill M Mitler; Kent E Moore; Barbara A Phillips; Stuart F Quan; Richard S Rosenberg; Thomas Roth; Helmut S Schmidt; Michael H Silber; James K Walsh; David P White
Journal:  J Clin Sleep Med       Date:  2005-01-15       Impact factor: 4.062

Review 6.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

Review 7.  Pathophysiology of restless legs syndrome: evidence for iron involvement.

Authors:  James R Connor
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

Review 8.  [Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

Authors:  S Happe; W Paulus
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

9.  Elevated estradiol plasma levels in women with restless legs during pregnancy.

Authors:  Andrea Dzaja; Renate Wehrle; Marike Lancel; Thomas Pollmächer
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

Review 10.  Sleep-related non epileptic motor disorders.

Authors:  Pasquale Montagna
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.